寧德時代(300750.SZ)繼續上漲創新高 逼近2400億的市值坐上創業板頭把交椅
格隆匯12月27日丨股價在24日已突破百元的寧德時代(300750.SZ)今日繼續上漲再創歷史新高價109.59元,現報108.2元,漲2.93%,暫成交9.12億元,最新總市值2389億元,已超過邁瑞醫療成為創業板市值最高的公司。該股年初至今累漲46%。業內人士稱,雖然鋰電池行業整體遇冷,但與此同時,強者恆強的馬太效應也正在上演。今年11月,寧德時代的市場佔有率已經達到64%,遠超緊隨其後的比亞迪和國軒高科,後兩者市佔率均在6%左右。寧德時代成為當之無愧的“巨無霸”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.